Bessemer Group Inc Travere Therapeutics, Inc. Transaction History
Bessemer Group Inc
- $61.3 Billion
- Q4 2024
A detailed history of Bessemer Group Inc transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Bessemer Group Inc holds 165 shares of TVTX stock, worth $3,780. This represents 0.0% of its overall portfolio holdings.
Number of Shares
165
Previous 165
-0.0%
Holding current value
$3,780
Previous $2,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding TVTX
# of Institutions
211Shares Held
91.8MCall Options Held
882KPut Options Held
811K-
Black Rock Inc. New York, NY7.64MShares$175 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.36MShares$169 Million1.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.74MShares$154 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.97MShares$114 Million3.46% of portfolio
-
Macquarie Group LTD Australia, C34.26MShares$97.6 Million0.09% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.47B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...